ZA200900478B - Pyrazole derivatives as cytochrome P450 inhibitors - Google Patents

Pyrazole derivatives as cytochrome P450 inhibitors

Info

Publication number
ZA200900478B
ZA200900478B ZA200900478A ZA200900478A ZA200900478B ZA 200900478 B ZA200900478 B ZA 200900478B ZA 200900478 A ZA200900478 A ZA 200900478A ZA 200900478 A ZA200900478 A ZA 200900478A ZA 200900478 B ZA200900478 B ZA 200900478B
Authority
ZA
South Africa
Prior art keywords
cytochrome
inhibitors
pyrazole derivatives
pyrazole
derivatives
Prior art date
Application number
ZA200900478A
Other languages
English (en)
Inventor
Simon Paul Planken
Scott Channing Sutton
Rongliang Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200900478B publication Critical patent/ZA200900478B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
ZA200900478A 2006-07-05 2009-01-21 Pyrazole derivatives as cytochrome P450 inhibitors ZA200900478B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80659606P 2006-07-05 2006-07-05
US91098807P 2007-04-10 2007-04-10
US94180807P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
ZA200900478B true ZA200900478B (en) 2010-04-28

Family

ID=38515807

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900478A ZA200900478B (en) 2006-07-05 2009-01-21 Pyrazole derivatives as cytochrome P450 inhibitors

Country Status (24)

Country Link
US (1) US7919488B2 (es)
EP (1) EP2046774A1 (es)
KR (1) KR20090034958A (es)
CN (1) CN101511812A (es)
AP (1) AP2009004763A0 (es)
AR (1) AR062154A1 (es)
AU (1) AU2007270814B2 (es)
CA (1) CA2660031A1 (es)
CO (1) CO6150178A2 (es)
CR (1) CR10573A (es)
EA (1) EA200900135A1 (es)
GT (1) GT200700053A (es)
IL (1) IL196490A0 (es)
MA (1) MA30629B1 (es)
MX (1) MX2009000482A (es)
NO (1) NO20090346L (es)
NZ (1) NZ574207A (es)
PE (1) PE20080998A1 (es)
RS (1) RS20090036A (es)
TN (1) TN2009000033A1 (es)
TW (1) TWI334867B (es)
UY (1) UY30460A1 (es)
WO (1) WO2008004096A1 (es)
ZA (1) ZA200900478B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754107B2 (en) * 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
AU2007349176A1 (en) * 2007-03-13 2008-09-18 Arete Therapeutics, Inc. 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ,インク. プロスタグランジンd2受容体のアンタゴニストとしての環式ジアリールエーテル化合物
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
WO2014000178A1 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070366A1 (en) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US20220144797A1 (en) * 2019-02-08 2022-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
EP1373263B1 (en) * 2001-04-05 2004-10-27 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7662844B2 (en) * 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
EA014329B1 (ru) 2005-09-23 2010-10-29 Пфайзер Продактс Инк. Пиридинаминосульфонилзамещенные бензамиды в качестве ингибиторов цитохрома р450 3а4 (cyp3a4)

Also Published As

Publication number Publication date
CO6150178A2 (es) 2010-04-20
NO20090346L (no) 2009-02-19
TW200811159A (en) 2008-03-01
CN101511812A (zh) 2009-08-19
UY30460A1 (es) 2008-02-29
US20080021011A1 (en) 2008-01-24
MA30629B1 (fr) 2009-08-03
EA200900135A1 (ru) 2009-06-30
CR10573A (es) 2009-02-12
US7919488B2 (en) 2011-04-05
RS20090036A (en) 2010-06-30
NZ574207A (en) 2010-10-29
KR20090034958A (ko) 2009-04-08
PE20080998A1 (es) 2008-08-15
AR062154A1 (es) 2008-10-22
TN2009000033A1 (fr) 2010-08-19
AU2007270814A1 (en) 2008-01-10
GT200700053A (es) 2009-08-03
TWI334867B (en) 2010-12-21
MX2009000482A (es) 2009-01-27
AP2009004763A0 (en) 2009-02-28
AU2007270814B2 (en) 2011-07-14
IL196490A0 (en) 2011-07-31
EP2046774A1 (en) 2009-04-15
CA2660031A1 (en) 2008-01-10
WO2008004096A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
IL196490A0 (en) Pyrazole derivatives as cytochrome p450 inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
HK1148520A1 (zh) 細胞色素 的抑制劑
EP2057158B8 (en) Triazole derivatives as kinase inhibitors
HK1134674A1 (en) Sulfoximines as kinase inhibitors
HK1117159A1 (en) Pyrrolidine derivatives as erk inhibitors
ZA200810673B (en) 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof
ZA200807447B (en) Thieno-Pyridine derivatives as MEK inhibitors
EP2078001B8 (en) Diazepane-acetamide derivatives as selective 11 -hsd1 inhibitors
EP2016080A4 (en) DIHYDROPYRAZOLOPYRIMIDINONDERIVATE
HK1134284A1 (en) Pyridizinone derivatives pyridizinone
EP2046333A4 (en) THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
EP2103607A4 (en) 1-phenyl-1-thio-D-GLUCITOLDERIVAT
EP2015745A4 (en) MACROCYCLIC KINASE INHIBITORS
IL197103A0 (en) Compositions for inhibiting cytochrome p450
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
HK1136276A1 (en) 5-hydroxymethyl-oxazolidin-2-one derivatives 5---2-
HK1191574A1 (zh) 作為 抑制劑的吡唑啉酮衍生物
EP2084135A4 (en) pyrazole
IL205602A0 (en) Pyrazole derivatives as 5-lo inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
HU0600272D0 (en) Aid for operations
GB0610018D0 (en) Benzotriazepinone derivatives
GB0610019D0 (en) Benzotriazepinone derivatives